Related Experiment Video
Updated: Feb 5, 2026

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
Deficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development
Sonia Leon-Cabrera1,2, Armando Vázquez-Sandoval3, Emmanuel Molina-Guzman4
1Unidad de Biomedicina. Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México (UNAM), Av. De los Barrios 1, Los Reyes Iztacala, Tlalnepantla, Edo. De México 54090, Mexico. soleon81@gmail.com.
Abstract:
Signal transducer and activator of transcription 1 (STAT1) is part of the Janus kinase (JAK/STAT) signaling pathway that controls critical events in intestinal immune function related to innate and adaptive immunity. Recent studies have implicated STAT1 in tumor⁻stroma interactions, and its expression and activity are perturbed during colon cancer. However, the role of STAT1 during the initiation of inflammation-associated cancer is not clearly understood. To determine the role of STAT1 in colitis-associated colorectal cancer (CAC), we analyzed the tumor development and kinetics of cell recruitment in wild-type WT or STAT1-/- mice treated with azoxymethane (AOM) and dextran sodium sulfate (DSS). Following CAC induction, STAT1-/- mice displayed an accelerated appearance of inflammation and tumor formation, and increased damage and scores on the disease activity index (DAI) as early as 20 days after AOM-DSS exposure compared to their WT counterparts. STAT1-/- mice showed elevated colonic epithelial cell proliferation in early stages of injury-induced tumor formation and decreased apoptosis in advanced tumors with over-expression of the anti-apoptotic protein Bcl2 at the colon. STAT1-/- mice showed increased accumulation of Ly6G⁺Ly6C-CD11b⁺ cells in the spleen at 20 days of CAC development with concomitant increases in the production of IL-17A, IL-17F, and IL-22 cytokines compared to WT mice. Our findings suggest that STAT1 plays a role as a tumor suppressor molecule in inflammation-associated carcinogenesis, particularly during the very early stages of CAC initiation, modulating immune responses as well as controlling mechanisms such as apoptosis and cell proliferation.
Insights
Signal transducer and activator of transcription 1 (STAT1) acts as a tumor suppressor in colitis-associated colorectal cancer (CAC). STAT1 deficiency accelerates inflammation and tumor growth by altering immune cell recruitment and cytokine production.
Area of Science:
- Immunology
- Oncology
- Gastroenterology
Background:
- Signal transducer and activator of transcription 1 (STAT1) is integral to the JAK/STAT pathway, governing intestinal immunity.
- STAT1's role in the early stages of inflammation-associated colorectal cancer (CAC) remains unclear.
- Tumor-stroma interactions and STAT1 activity are altered in colon cancer.
Purpose of the Study:
- To investigate the function of STAT1 in the initiation and development of colitis-associated colorectal cancer (CAC).
- To analyze tumor progression and immune cell dynamics in STAT1-deficient mice during CAC induction.
Main Methods:
- Utilized wild-type (WT) and STAT1-deficient (STAT1-/-) mice treated with azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce CAC.
- Monitored tumor development, disease activity index (DAI), colonic epithelial cell proliferation, apoptosis, and immune cell infiltration (Ly6G⁺Ly6C⁻CD11b⁺).
- Quantified cytokine production (IL-17A, IL-17F, IL-22) in spleen samples.
Main Results:
- STAT1-/- mice exhibited accelerated inflammation and tumor formation with higher DAI scores early in CAC development compared to WT mice.
- STAT1 deficiency led to increased colonic epithelial cell proliferation and decreased apoptosis in advanced tumors, with Bcl2 overexpression.
- Increased accumulation of specific immune cells (Ly6G⁺Ly6C⁻CD11b⁺) and elevated pro-inflammatory cytokines (IL-17A, IL-17F, IL-22) were observed in STAT1-/- mice.
Conclusions:
- STAT1 functions as a tumor suppressor in inflammation-associated carcinogenesis, particularly in the early stages of CAC.
- STAT1 modulates immune responses and controls key cellular mechanisms like apoptosis and proliferation during CAC initiation.
- Targeting STAT1 may offer therapeutic strategies for preventing or treating early-stage colorectal cancer.
Related Concept Videos
Inflammation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Endocrine Signaling
Bacterial Signaling
Yeast Signaling
What is Cell Signaling?

